Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Bonaca, Marc; Nault, Patrice; Giugliano, Robert; Keech, Anthony; Pineda, Armando; Kanevsky, Estella; Kuder, Julia; Murphy, Sabina; Jukema, J.; Lewis, Basil; Tokgozoglu, SADBERK; Somaratne, Ransi; Sever, Peter; Pedersen, Terje; Sabatine, Marc

doi:10.1161/circulationaha.117.032235

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Bonaca M. P., Nault P., Giugliano R. P., Keech A. C., Pineda A. L., Kanevsky E., ...More

CIRCULATION, vol.137, no.4, pp.338-350, 2018 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 137 Issue: 4
Publication Date: 2018
Doi Number: 10.1161/circulationaha.117.032235
Journal Name: CIRCULATION
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.338-350
Open Archive Collection: AVESIS Open Access Collection
Hacettepe University Affiliated: Yes

Abstract

Background: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on major adverse limb events.